AMLN Amylin Pharmaceuticals, Inc. (MM)

Data Disclosure Through Company-Sponsored Webcast SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that data featuring its approved drugs and pipeline candidates will be presented at the 66th Annual Scientific Sessions of the American Diabetes Association (ADA) being held in Washington, DC from June 9 to 13. The company will also host an investor conference during the meeting that will be available by webcast. ADA is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and the delivery of diabetes care. Data from several studies will be highlighted in oral presentations and poster sessions offering insight into Amylin's approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and the company's research and development programs. Additional information will also be presented during two symposia focused on the use of incretin hormones for type 2 diabetes and new approaches to obesity treatment. "Amylin remains dedicated to its founding mission of discovering, developing and bringing to market innovative new medicines with life-changing therapeutic potential," said Ginger Graham, President and Chief Executive Officer, Amylin Pharmaceuticals, Inc. "At ADA 2006, new evidence supporting the benefits of BYETTA(R) and SYMLIN(R) and revealing the potential of peptide hormones to treat obesity will be presented." KEY AMYLIN ABSTRACTS BEING PRESENTED AT ADA: 1. Late Breaking Poster: Leptin Responsivity Restored in Leptin-Resistant Diet-Induced Obese (DIO) Rats: Synergistic Actions of Amylin and Leptin for Reduction in Body Weight (BW) and Fat This pre-clinical study will examine the effects of using a combination treatment of amylin and leptin to treat obesity in rat models. Jonathan Roth, Ph.D., Senior Staff Scientist at Amylin, will present the data during scheduled times throughout the conference and at the evening Poster Session Reception on Sunday, June 11 at 6:30 PM ET. 2. Oral: Safety and Efficacy of Exenatide in Patients with Type 2 Diabetes Mellitus Using Thiazolidenediones with or without Metformin The randomized, placebo-controlled, parallel, double-blind trial will provide new data on the safety and efficacy of combination therapy of BYETTA(R) and a thiazolidenedione (TZD). Bernard Zinman, M.D. will present the study's findings on Saturday, June 10 at 10:15 AM ET. 3. Oral: Effects of Exenatide on Gastric Emptying and Postprandial Glucose in Type 2 Diabetes Results from the first, randomized study to investigate the impact of BYETTA(R) on stomach (gastric) emptying and after-meal (postprandial) glucose levels will be presented by Helle Linnebjerg, Ph.D. on Saturday, June 10 at 10:15 AM ET. 4. Poster: Safety and Effects of a Once-Weekly, Long-Acting Release Formulation of Exenatide Over 15 Weeks in Patients with Type 2 Diabetes This randomized, double-blind, placebo-controlled trial exploring the safety and efficacy of the exenatide long-acting release (LAR) formulation for type 2 diabetes will be presented during a poster session on Sunday, June 11 at 12:00 PM ET. A full list of all 12 Amylin abstracts being presented at ADA is available at: http://scientificsessions.diabetes.org/. FEATURED SYMPOSIA: 1. Can We Cut Our Losses? New Approaches to Obesity This ADA-hosted symposium will feature a presentation highlighting Pramlintide, a synthetic analog of the islet hormone amylin, given by Alain Baron, M.D., Senior Vice President, Research at Amylin. The symposium will take place on Sunday, June 11 at 8:00 AM ET. 2. Filtering Through the Evidence: A 2006 Update on Incretins in Type 2 Diabetes This medical education symposium will help physicians, nurses and pharmacists understand the complex role that incretins play as therapeutic agents for type 2 diabetes. The symposium will be chaired by Christopher Saudek, M.D. and will be held on Monday, June 12 at 5:30 AM ET. This symposium is supported by an unrestricted educational grant from Amylin Pharmaceuticals and Eli Lilly and Co. Amylin will also conduct a webcast for investors to review the information presented at ADA on Sunday, June 11 at 7:00 PM ET. The live presentation will be webcast and a recording made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com/. To access the live webcast, please log on to Amylin's site approximately 15 minutes prior to the presentation to register and download any necessary audio software. "The data presented at ADA this year speaks to the breadth and depth of our R&D enterprise. We're confident that our focus on neurohormones with multiple actions holds potential for a robust product pipeline now, and well into the future," said Ms. Graham. More information about ADA can be found at http://scientificsessions.diabetes.org/. About Amylin Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop promising therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1200 employees nationwide. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com/. This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA or SYMLIN may be affected by unexpected new data, technical issues, or manufacturing and supply issues; risks that the results of pre-clinical studies or clinical trials may not be predictive of future results; risks that our clinical trials will not start or be completed when planned; risks that the FDA may not approve the Company's regulatory submissions; and risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's recently filed prospectus supplement. Amylin disclaims any obligation to update these forward-looking statements. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Media, Alice Bahner of Amylin Pharmaceuticals, Inc., +1-858-552-2200, or cell, +1-858-232-9072, ; or Lorie Fiber of Edelman, +1-323-202-1046, or cell, +1-310-383-6583, , for Amylin Pharmaceuticals, Inc. Web site: http://www.amylin.com/ http://scientificsessions.diabetes.org/

Copyright